Table 2. Special clinical characteristics related to IBD subjects.
| Clinical characteristics and medications | IBD subjects (n=8) |
|---|---|
| IBD type | |
| CD/UC | 5 (62.5%)/3 (37.5%) |
| Medicationsa | |
| Steroids | 1 (12.5%) |
| Oral 5-ASAs | 6 (75%) |
| Purine analogs | 3 (37.5%) |
| TNF inhibitors | 1 (12.5%) |
| Disease activity | |
| HBAI <5 (CD subjects) (remission) | 4 (80%) |
| HBAI <7 (CD subjects) (mild disease) | 1 (20%) |
| HBAI ≥8 (CD subjects) (moderate-to-severe disease) | 0 |
| UAI <3 (UC subjects) (remission) | 3 (100%) |
| UAI ≥4 (UC subjects) (active disease) | 0 |
| Time since diagnosis (years) | 18.3 (±7.2) |
| Time since last flare (weeks) | 5.87 (±2.4) |
| Number of flares since diagnosis | 6.7 (±6.3) |
| Symptoms | |
| Abdominal pain | 1 (12.5%) |
| Blood in stool | 1 (12.5%) |
| Extraintestinal manifestations | 1 (12.5%) |
| Disease behavior (CD subjects) | |
| Inflammatory (B1)/stricturing (B2)/fistulizing (B3)/perianal disease (p) | 2 (40%)/2 (40%)/1 (20%)/1 (20%) |
| Disease location (CD subjects) | |
| Ileal (L1)/colonic (L2)/iIeocolonic (L3)/isolated upper disease (L4) | 0/1 (20%)/4 (80%)/0 |
| Maximal disease extent (UC subjects) | |
| Ulcerative proctitis (E1)/left sided (E2)/pancolitis (E3) | 0/0/3 (100%) |
ASAs, aminosalicylates; CD, Crohn's disease; HBAI, Harvey–Bradshaw activity index; IBD, inflammatory bowel disease; TNF, tumor necrosis factor; UAI, ulcerative colitis disease activity index; UC, ulcerative colitis.
n (%) or mean±s.d.
a
Numbers may not add up to 100% since some patients were using more than one type of medication.